Opinion

Video

KarMMA-3: Trial of Ide-Cel in Patients with Triple Class Exposed R/R MM

Experts discuss the recent data presented at ASH 2023 from the KarMMA-3 trial in which ide-cel vs standard of care was studied in triple class exposed R/R MM patients.

This is a video synopsis/summary of an OncLive® Post-Conference Perspective involving Rafat Abonour, MD, and Noopur Raje, MD.

Abonour and Raje discuss results from the phase 3 KarMMa-3 trial of B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) vs standard of care in relapsed/refractory multiple myeloma after 2 to 4 prior lines of therapy. A total of 386 patients were randomly assigned 2:1 to receive ide-cel or standard-of-care regimens containing daratumumab, pomalidomide, and dexamethasone; daratumumab, bortezomib, and dexamethasone; ixazomib, lenalidomide, and dexamethasone; carfilzomib and dexamethasone; or elotuzumab, pomalidomide, and dexamethasone.

At a median follow-up of 31 months, ide-cel demonstrated superior progression-free survival compared with control (13.8 months vs 4.4 months, respectively). Objective response rate and duration of response also favored ide-cel. Crossover from the control arm to ide-cel was allowed, confounding overall survival analyses, but ide-cel showed consistent benefit across secondary end points.

Importantly, no new safety signals emerged with longer follow-up. Rates of cytokine release syndrome (5%) and neurotoxicity (3%) remain consistent with the known safety profile.

Abonour and Raje conclude that this robust data set supports using BCMA-targeted CAR T-cell therapy earlier in the treatment paradigm for patients with multiple myeloma, whereas it is currently approved in later-line settings. The safety profile remains manageable without emergence of delayed adverse events.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Ajay K. Nooka, MD, MPH, FACP
Meletios A. Dimopoulos, MD
Binod Dhakal, MD
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique toxicities like cytokine release syndrome (CRS) and the need for well-defined protocols to ensure patient safety and effective treatment.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique adverse effects, such as cytokine release syndrome and infection risks.
Jill Corre, PharmD, PhD
Jill Corre, PharmD, PhD